Submission of Leqembi® sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/submission-of-leqembi-lecanemab-irmb-sbla-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-to-the-us-fda-completed-302104249.html
en | boerse | 67934295 |
